AOD-9604

At a glance

What is AOD-9604?

AOD-9604 stands for Advanced Obesity Drug 9604. It's a synthetic peptide — a chain of 16 amino acids — corresponding to the C-terminal fragment (amino acids 177-191) of human growth hormone, with an added tyrosine at the N-terminus for stability.^[1]

The compound was developed in the 1990s at Monash University in Australia by Professor Frank Ng's laboratory. The core idea was elegant: growth hormone has both growth-promoting effects (which raise IGF-1, affect blood sugar, and can cause tissue overgrowth) and fat-burning effects. Could you isolate just the fat-burning part? AOD-9604 was the attempt to do exactly that.^[3]

In that narrow sense, the science worked. AOD-9604 does not raise IGF-1, does not disrupt glucose metabolism, and does not cause the hormonal side effects associated with full-length growth hormone. That metabolic selectivity is well-established across multiple human trials.

The problem came when researchers tested whether this metabolically selective compound actually caused meaningful weight loss in humans. It did not — at least not at the doses tested in the pivotal trial.

How it works

In plain terms, AOD-9604 is designed to activate the fat-burning part of growth hormone's activity without triggering the growth-promoting part. In animal studies, it stimulates the breakdown of stored fat (lipolysis) and inhibits the formation of new fat (lipogenesis).^[2]

Think of growth hormone as having two major functions: one that tells cells to grow (which also raises IGF-1 and can affect blood sugar) and one that tells fat cells to release their stored energy. AOD-9604 was engineered to activate only the second function.

What the research says

AOD-9604 is a rare case where the clinical story is clear — and negative. It was well tolerated across 900+ human participants taking it orally. But it failed its pivotal Phase IIb trial for weight loss in 2007, and no new human trial has been run since. Everything marketed about this compound should be read in that context.

Research timeline

AOD-9604 has a more complete clinical history than most research peptides — which makes the gap between marketing claims and actual evidence especially notable:

Human clinical trials

AOD-9604 has more human clinical data than most research peptides — which makes the evidence picture both clearer and more sobering. Six controlled trials were conducted with 900+ total participants. Here are the key results:

The injectable question

There is another critical fact that is almost never disclosed in marketing: all human clinical trials of AOD-9604 used oral dosing. The injectable subcutaneous form — which is what most clinics have sold and most consumers have used — was never tested in a published human trial.

This means we have no controlled human data on:

• Whether injectable AOD-9604 produces different effects than oral
• What the appropriate injectable dose is
• Whether the pharmacokinetics differ by route
• Whether the safety profile changes with subcutaneous administration

The oral form was tested, and it failed for efficacy. The injectable form was never tested at all.

Animal studies

The preclinical evidence is where AOD-9604 looked most promising. Multiple studies from Monash University showed significant fat reduction in obese animal models:^[2]

What the evidence shows

People come to AOD-9604 with specific expectations — usually about fat loss. Here's what the published research actually tells us about each major claim:

Safety & side effects

What research shows

Tolerability is the strongest part of AOD-9604's evidence profile, and it comes from real clinical trials with hundreds of participants.^[6]

Across 6 randomized, double-blind, placebo-controlled trials involving more than 900 participants:

• No serious adverse events attributable to AOD-9604 in any trial
• No anti-AOD-9604 antibody formation in any participant
• No glucose intolerance or insulin resistance (confirmed by oral glucose tolerance tests)
• No IGF-1 elevation
• No hormonal disruption of any kind — testosterone, estrogen, cortisol, thyroid hormones all unaffected
• Safety profile described as "indistinguishable from placebo" in the Phase IIb trial

The most commonly reported adverse events were mild and occurred at rates similar to placebo: headache, mild facial flushing, and fatigue.^[7]

What the FDA has said

That trial record is not the whole picture, and the profile you read on most vendor sites stops there. In the safety rationale published alongside its bulk-substance categories — page content current as of April 22, 2026 — the FDA states that it "has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear."^[13]

Two things are true at once, and both matter:

• The published pooled analysis of six oral trials found tolerability indistinguishable from placebo.
• FDA, reviewing material that includes unpublished data submitted during the compounding nomination process, says it identified serious adverse events it could not rule in or out.

FDA does not claim causality, and neither do we. But an agency statement of that kind belongs next to the "excellent safety record" framing, not behind it. AOD-9604 was one of six peptides — alongside GHRP-2, ibutamoren, ipamorelin, CJC-1295 and melanotan II — whose 2023 Category 2 placements rested on documented immunogenicity risk and adverse events in study subjects.

A 2026 review in Sports Medicine covering AOD-9604 and the other GH-axis peptides reaches the same summary judgment: animal data are favorable, rigorous human safety data are scarce, and the potential for serious harm is real.^[14]

Community-reported side effects

Among people who have used AOD-9604 outside of clinical settings (primarily via subcutaneous injection — a route not tested in clinical trials), commonly reported effects include:

• Injection-site redness, swelling, or tenderness
• Mild nausea (infrequent)
• Mild water retention
• Headache
• Stomach discomfort

These are self-reported and not from controlled studies.

Limitations of the safety data

How people use it

AOD-9604 has been used primarily in the context of fat loss and, more recently, joint health. Here's what the landscape of use looks like — with important caveats.

Administration routes

• Subcutaneous injection (most common in practice): Injected in the abdomen, typically in a fasted state. This is the most common route used by clinics and consumers — but it was never tested in the clinical trials, which used oral dosing.
• Oral capsule/troche: More aligned with the form actually tested in clinical trials, though that form failed for efficacy at the doses tested.

Common stacking context

In clinical and community practice, AOD-9604 has been discussed alongside other compounds:

• AOD-9604 + CJC-1295/Ipamorelin — sometimes combined for additive fat-loss effects. No evidence for synergy with AOD-9604 specifically.
• AOD-9604 + BPC-157 — sometimes added for joint health claims. No combination data exists.
• AOD-9604 + Hyaluronic acid — one rabbit study showed enhanced cartilage regeneration with the combination vs. either alone.^[8]

All stacking protocols are practitioner-derived or community-derived and have not been studied in any controlled human setting.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

Legal & regulatory status

As of August 2026:

FDA status

AOD-9604 is not FDA-approved for any indication in any country. It has a more complex regulatory history than most research peptides:

• September 2023: FDA classified AOD-9604 as a Category 2 bulk drug substance, effectively banning compounding.^[13]
• September 2024: The nominator withdrew its nomination. AOD-9604 now appears in FDA's "nominated but withdrawn" table rather than the active Category 2 table.
• December 4, 2024: The Pharmacy Compounding Advisory Committee (PCAC) voted against recommending AOD-9604 for the 503A bulks list. The FDA briefing document cited lack of safety data for the injectable form and immunogenicity concerns.^[10]
• April 22, 2026: The most recent update to FDA's category page. AOD-9604's status is unchanged, and FDA's stated safety rationale — serious adverse events of unclear causality — remains published alongside it.^[13]

WADA / USADA status

AOD-9604 is prohibited at all times under WADA Section S2.2.3 — growth hormone, its analogues and fragments. The 2026 Prohibited List names it explicitly, in the bullet covering "growth hormone fragments, e.g. AOD-9604 and hGH 176-191."^[12]

This is a correction worth stating plainly, because the S0 (non-approved substances) classification is repeated across a great deal of peptide writing, including an earlier version of this page. It matters for one concrete reason: every S2 substance is non-Specified, while everything in S0 is a Specified Substance. Non-Specified status generally means a heavier sanction and a harder path to reducing it. If you are subject to anti-doping testing, this is not a technicality.

WADA also issued a specific clarifying statement in April 2013 confirming AOD-9604 was banned, following confusion that arose from an Australian Crime Commission investigation. That statement is history, not the current classification.^[11]

International status

AOD-9604 is not approved for clinical use in any country. Development was abandoned in 2007 by Metabolic Pharmaceuticals after the Phase IIb failure. The IP changed hands multiple times (Metabolic Pharmaceuticals to Calzada to PolyNovo to Lateral Pharmaceuticals) and was redesignated LAT8881, but no new human efficacy trials have been conducted.

How AOD-9604 compares

The most instructive comparison is between AOD-9604 — a compound that failed its weight loss trial — and semaglutide, which succeeded:

The contrast is stark and instructive. AOD-9604 was tested in 900+ participants and failed its primary efficacy endpoint. Semaglutide was tested in 17,000+ participants and achieved FDA approval for both diabetes and obesity, with weight loss of 15-20% of body weight in clinical trials.

If you're considering a peptide for weight management, this comparison matters. One compound has proven efficacy data; the other does not. AOD-9604's genuine advantage — metabolic selectivity without hormonal side effects — is real but does not compensate for the lack of proven weight loss.

One more asymmetry worth naming: semaglutide's evidence base keeps growing. AOD-9604's has not moved in nineteen years.